CD8A and neoplasm: Importantly, combining CD4+ and CD8+ T cells at a 1:1 ratio—whether iPSC-derived or primary—resulted in intermediate levels of tumor control, T cell proliferation, and cytokine production, without surpassing the performance of the CD4+ T cell alone.